Adding anatomic and clinical pathology endpoints in discovery studies enhances the understanding, characterization and translational ability of animal models, as well as allows for comparison of developmental candidates and lead optimization and provides, in some cases, early efficacy information.
Charles River combines expertise from our discovery, research models and preclinical services groups with our pathology expertise to provide clients with a comprehensive approach to animal model evaluation for specialized therapeutic areas, including oncology, cardiovascular, respiratory, CNS, ophthalmology, inflammation and metabolic disease.